Sage Therapeutics and Biogen's Phase 2 KINETIC 2 study for essential tremor treatment with SAGE-324 failed, causing stock collapse.
Sage Therapeutics and Biogen's Phase 2 KINETIC 2 study for essential tremor treatment failed, causing Sage's stock to collapse. The drug, SAGE-324, did not show a statistically significant improvement in tremor or activities of daily living among patients. Both companies have decided to halt the ongoing study and consider potential alternative uses for the drug.
July 24, 2024
5 Articles